PIPA532675
Bombesin Receptor 3 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA532675-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA532675 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
Bombesin Receptor 3
Classification
Polyclonal
Conjugate
Unconjugated
Gene
BRS3
Gene Alias
BB3; BB3R; bombesin like receptor 3; bombesin receptor subtype 3; bombesin receptor subtype-3; bombesin-like receptor 3; BRS 3; BRS3; BRS-3; G-protein coupled receptor; RP1-196E23.3
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
680
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
ELISA, Immunohistochemistry (Paraffin)
Concentration
1 mg/mL
Formulation
PBS with 0.1% sodium azide
Gene Accession No.
P32247
Gene Symbols
BRS3
Immunogen
Synthetic 16 amino acid peptide from C-terminal cytoplasmic domain of human BRS3.
Quantity
50 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Percent identity with other species by BLAST analysis: Human, Gorilla, Gibbon (100%); Monkey (94%); Marmoset (81%)
- For IHC(P), use heat induced antigen retrieval in pH 6.0 citrate buffer
- After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen
- BRS3 expression has been reported in lung (normal and cancer), nasal mucosa, placenta, and uterus
- ESTs have been isolated from normal brain and kidney cancer libraries
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This "eturn-off"e activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.